Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zhang, Shanshan ^a   Sun, Xiaoxi ^b   Chang, Wenjiao ^b   Dai, Yuanyuan ^b   Ma, Xiaoling ^b  

^a SHANDONG UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ASIA; BACTERIAL STRAIN; DRUG TREATMENT FAILURE; EUROPE; GENOTYPE; HOSPITAL INFECTION; HUMAN; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PREVALENCE; REVIEW; STAPHYLOCOCCUS AUREUS; SYSTEMATIC REVIEW; TREND STUDY; WESTERN HEMISPHERE; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE;

GENES, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; VANCOMYCIN RESISTANCE;

EID: 84942791837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136082     Document Type: Review

References (124)

1. Lowy FD. Staphylococcus aureus infections. The New England journal of medicine. 1998;339(8):520-32. Epub 1998/08/26. doi: 10.1056/nejm199808203390806 PMID: 9709046.
2. M CL, D RS, B-V S, M K, M LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis. 2007;13(2):236-42. PMID: 17479885
3. LC M. Trends in Antimicrobial Resistance in Health Care-Associated Pathogens and Effect on Treatment. Clinical Infectious Diseases. 2006;42 (2).
4. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerging infectious diseases. 2004;10(6):1125-8. PMID: 15207068
5. H K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. The Lancet Infectious Diseases. 2001;1(3):147-55. PMID: 11871491
6. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis. 2001;32(1):108-15. Epub 2000/12/19. doi: 10.1086/317542 PMID: 11118389.
7. H K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. The American Journal of Medicine. 1998;(5A):7S-10S.
8. R MJ, A RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs. 2001; volume 61(1):1-7 ().
9. Hal SJv, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(1):405-10. doi: 10.1128/AAC.01133-10 PMID: 21078939
10. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 1999;353(9164):1587-8. Epub 1999/05/20. PMID: 10334262.
11. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. Journal of clinical microbiology. 2000;38(10):3879-81. Epub 2000/10/04. PMID: 11015427; PubMed Central PMCID: PMCPmc87500.
12. Sng LH, Koh TH, Wang GC, Hsu LY, Kapi M, Hiramatsu K. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore. International journal of antimicrobial agents. 2005;25(2):177-9. Epub 2005/01/25. PMID: 15664490.
13. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003;47(10):: 3040-5. PMID: 14506006
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959;15(4):639-40.
15. Dersimonian R, Laird N. N: Meta-analysis in clinical trials. Controlled Clinical Trials. 1986.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58. Epub 2002/07/12. doi: 10.1002/sim.1186 PMID: 12111919.
17. Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. ANNALS OF MATHEMATICAL STATISTICS. 1950;6(2):180-.
18. Garnier F, Chainier D, Walsh T, Karlsson A, Bolmstrom A, Grelaud C, et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. The Journal of antimicrobial chemotherapy. 2006;57(1):146-9. doi: 10.1093/jac/dki413 PMID: 16286482.
19. Hanaki H, Cui L, Ikeda-Dantsuji Y, Nakae T, Honda J, Yanagihara K, et al. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy. 2014;20(9):527-34. PMID: 25066429.
20. WSS, H PL, WPC, Y KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clinical Infectious Diseases. 1999;29(4):760-7. PMID: 10589883
21. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycinheteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). Journal of clinical microbiology. 2008;46(9):2950-4. doi: 10.1128/JCM. 00582-08 PMID: 18632899; PubMed Central PMCID: PMC2546725.
22. Pastagia M, Kleinman L, Huprikar S, Jenkins S. Clinical and bacteriologic characteristics of a 5-year cohort of MRSA patients at a large U. S. metropolitan hospital. Clinical Microbiology and Infection. 2009;15:S20-S1.
23. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology.. 2009;28(8):983-7. Epub 2009/04/24. doi: 10.1007/s10096-009-0741-5 PMID: 19387707.
24. C PG, WPB, J PD, H BP, G ML. Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus. Clinical Infectious Diseases. 2004;38(3):448-51. PMID: 14727222
25. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. The Journal of infectious diseases. 2009;199(5):619-24. doi: 10.1086/596629 PMID: 19199552.
26. Hsueh PR, Lee SY, Perng CL, Chang TY, Lu JJ. Clonal dissemination of meticillin-resistant and vancomycinintermediate Staphylococcus aureus in a Taiwanese hospital. International journal of antimicrobial agents. 2010;36(4):307-12. PMID: 20685086.
27. Kim MN, Hwang SH, Pyo YJ, Mun HM, Pai CH. Clonal Spread of Staphylococcus aureus Heterogeneously Resistant to Vancomycin in a University Hospital in Korea. Journal of clinical microbiology. 2002;40(4):1376-80. doi: 10.1128/jcm.40.4.1376-1380.2002 PMID: 11923359
28. Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, et al. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. The Journal of antimicrobial chemotherapy. 2012;67(8):1843-9. doi: 10.1093/jac/dks131 PMID: 22535621.
29. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2012;56(11):5845-51. doi: 10.1128/AAC.01139-12 PMID: 22948864; PubMed Central PMCID: PMC3486570.
30. dL A, H N, T JF, J-G ML, T G, B A, et al. Control And Outcome Of A Large Outbreak Of Colonization And Infection With Glycopeptide-Intermediate Staphylococcus Aureus In An Intensive Care Unit. Clinical Infectious Diseases. 2006;42(2):170-8. PMID: 16355325
31. Kaleem F, Usman J, Amanat S. Current status of Glycopeptide intermediate and heterogenous Glycopeptide intermediate Staphylococcus aureus and their prevailing susceptibility pattern at two tertiary care hospitals of Pakistan. International Journal of Infectious Diseases. 2012;16:e420-e1. doi: 10. 1016/j.ijid.2012.05.582
32. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. The Journal of antimicrobial chemotherapy. 2006;57(3):506-10. doi: 10.1093/jac/dki486 PMID: 16410265.
33. Adam HJ, Louie L, Watt C, Gravel D, Bryce E, Loeb M, et al. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrobial agents and chemotherapy. 2010;54(2):945-9. doi: 10.1128/AAC.01316-09 PMID: 19949062; PubMed Central PMCID: PMC2812162.
34. Takata T. Detection of Heterogeneous Vancomycin Intermediate Staphylococcus aureus (hetero-VISA) in MRSA of Japanese Clinical Isolates. American Journal of Infection Control. 2009;37(5):E15-E6.
35. Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, et al. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. Journal of clinical microbiology. 2011;49(12):4203-7. doi: 10.1128/JCM.01152-11 PMID: 21976769; PubMed Central PMCID: PMC3232953.
36. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. The Lancet. 1997;350(9092):1670-3.
37. Van Hal SJ, Barbagiannakos T, Mercer J, Chen D, Gosbell IB, Paterson DL. Emergence and evolution of heteroresistant vancomycin intermediate Staphylococcus aureus in a single hospital over a 12-year period. Clinical Microbiology and Infection. 2011;17:S58.
38. Song JH, Hiramatsu K, Suh JY, Ko KS, Ito T, Kapi M, et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrobial agents and chemotherapy. 2004;48(12):4926-8. doi: 10.1128/AAC.48.12.4926-4928.2004 PMID: 15561884; PubMed Central PMCID: PMC529235.
39. Geisel R, Schmitz FJ, Thomas L, Berns G, Zetsche O, Ulrich B, et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. The Journal of antimicrobial chemotherapy. 1999;43(6):846-8. Epub 1999/07/15. PMID: 10404328.
40. Gowrishankar S, Thenmozhi R, Balaji K, Pandian SK. Emergence of methicillin-resistant, vancomycinintermediate Staphylococcus aureus among patients associated with group A Streptococcal pharyngitis infection in southern India. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases.. 2013;14:383-9. doi: 10.1016/j.meegid.2013.01.002 PMID: 23337611.
41. Denis O. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. Journal of Antimicrobial Chemotherapy. 2002;50(3):383-91. doi: 10. 1093/jac/dkf142 PMID: 12205063
42. SK F. Epidemiological and Microbiological Characterization of Infections Caused by Staphylococcus aureus with Reduced Susceptibility to Vancomycin, United States, 1997-2001. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America.. 2003;36(4):429-39.
43. Lewis T, Chaudry R, Das I, Lambert P. Epidemiology of MRSA bacteraemia and clinical relevance of reduced susceptibility to vancomycin. Clinical Microbiology and Infection. 2009;15:S544-S5.
44. Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2014;58(8):4636-41. doi: 10.1128/AAC.02820-13 PMID: 24890596; PubMed Central PMCID: PMC4136033.
45. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T, et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. Journal of clinical microbiology. 2001;39(2):591-5. doi: 10.1128/JCM.39.2.591-595.2001 PMID: 11158112; PubMed Central PMCID: PMC87781.
46. Lulitanond A, Engchanil C, Chaimanee P, Vorachit M, Ito T, Hiramatsu K. The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand. Journal of clinical microbiology. 2009;47(7):2311-6. doi: 10.1128/JCM.01749-08 PMID: 19403764; PubMed Central PMCID: PMC2708526.
47. K A, R K, S S, T MS, S AR, H MM, et al. Frequency of Reduced Vancomycin Susceptibility and Heterogeneous Subpopulation in Persistent or Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia. Clin Infect Dis. 2004;38(9):1328-30. PMID: 15127350
48. El Ayoubi MD, Hamze M, Mallat H, Achkar M, Dabboussi F. Glycopeptide intermediate Staphylococcus aureus and prevalence of the luk-PV gene in clinical isolates, in Northern Lebanon. Medecine et maladies infectieuses. 2014;44(5):223-8. doi: 10.1016/j.medmal.2014.03.004 PMID: 24835167.
49. H SK, M JM, F SK, G RP, J M Jr, T FC. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U. S. hospitals. Journal of clinical microbiology. 1999;37:: 3590-3. PMID: 10523558
50. M A, B G, T E, D EA, S GC. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. Journal of clinical microbiology. 2000;(2):866-9.
51. Chaudhari CN, Tandel K, Grover N, Sen S, Bhatt P, Sahni AK, et al. Heterogeneous vancomycinintermediate among methicillin resistant Staphylococcus aureus. Medical journal, Armed Forces India. 2015;71(1):15-8. PMID: 25609857; PubMed Central PMCID: PMC4297820.
52. Campanile F, Borbone S, Perez M, Bongiorno D, Cafiso V, Bertuccio T, et al. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. International journal of antimicrobial agents. 2010;36(5):415-9. PMID: 20727722.
53. Delgado A, Riordan JT, Lamichhane-Khadka R, Winnett DC, Jimenez J, Robinson K, et al. Heterovancomycinintermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico. Journal of clinical microbiology. 2007;45(4):1325-9. doi: 10.1128/JCM. 02437-06 PMID: 17267639; PubMed Central PMCID: PMC1865829.
54. Uckay I, Bernard L, Buzzi M, Harbarth S, Francois P, Huggler E, et al. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillinresistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2012;56(3):1258-64. doi: 10.1128/AAC.05808-11 PMID: 22155824; PubMed Central PMCID: PMC3294919.
55. Wang JL, Lai CH, Lin HH, Chen WF, Shih YC, Hung CH. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients. International journal of antimicrobial agents. 2013;42(5):390-4. PMID: 24041465.
56. Neoh H-M, Hori S, Komatsu M, Oguri T, Takeuchi F, Cui L, et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Annals of Clinical Microbiology and Antimicrobials. 6:13:: 13.
57. Kosowska-Shick K, Ednie LM, McGhee P, Smith K, Todd CD, Wehler A, et al. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicrobial agents and chemotherapy. 2008;52(12):4510-3. doi: 10.1128/AAC.01073-08 PMID: 18838583; PubMed Central PMCID: PMC2592881.
58. Chen H, Liu Y, Sun W, Chen M, Wang H. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC. Diagnostic microbiology and infectious disease. 2011;71(3):301-3. PMID: 21856109.
59. Reverdy ME, Jarraud S, Bobin-Dubreux S, Burel E, Girardo P, Lina G, et al. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases.. 2001;7(5):267-72.
60. Fitzgibbon MM, Rossney AS, O'Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. Journal of clinical microbiology. 2007;45(10):3263-9. doi: 10.1128/JCM.00836-07 PMID: 17687008; PubMed Central PMCID: PMC2045355.
61. Nakipoglu Y, Derbentli S, Cagatay AA, Katranci H. Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital. BMC infectious diseases. 2005;5:31. doi: 10.1186/1471-2334-5-31 PMID: 15871748; PubMed Central PMCID: PMC1156892.
62. Silveira AC, Sambrano GE, Paim TG, Caierao J, Cordova CM, D'Azevedo PA. Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides/lipopeptides? Diagnostic microbiology and infectious disease. 2014;79(4):401-4. PMID: 24906792.
63. E JM, L C, M M, WEM, P J, G JL, et al. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clinical Infectious Diseases. 2005;40(11):1617-24. PMID: 15889359
64. Fink SL, Martinello RA, Campbell SM, Murray TS. Low prevalence of heterogeneous vancomycinintermediate Staphylococcus aureus isolates among Connecticut veterans. Antimicrobial agents and chemotherapy. 2012;56(1):582-3. doi: 10.1128/AAC.05024-11 PMID: 22064529; PubMed Central PMCID: PMC3256079.
65. N C, D O, S MJ. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clinical Microbiology and Infection. 2005;11(3):214-20. PMID: 15715719
66. C GL, C M, B D, L M, B A, Bacteriologists Ao H, et al. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clinical Microbiology and Infection. 2004;10(5):448-51. PMID: 15113324
67. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. The Journal of antimicrobial chemotherapy. 2005;56(3):519-23. doi: 10.1093/jac/dki272 PMID: 16046461.
68. Panomket P, Thirat S, Wanram S, Sranujit RP. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2014;97 Suppl 4:S7-11. Epub 2014/05/24. PMID: 24851558.
69. WM, H RA, H R, WTR, B PM, M AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. Journal of Antimicrobial Chemotherapy. 2001;47(4):399-403. PMID: 11266410
70. Wang WY, Lee SY, Chiueh TS, Lu JJ. Molecular and phenotypic characteristics of methicillin-resistant and vancomycin-intermediate staphylococcus aureus isolates from patients with septic arthritis. Journal of clinical microbiology. 2009;47(11):3617-23. doi: 10.1128/JCM.00539-09 PMID: 19759226; PubMed Central PMCID: PMC2772649.
71. Liu C, Chen ZJ, Sun Z, Feng X, Zou M, Cao W, et al. Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2014. PMID: 24767415.
72. Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Siu LK, et al. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2012;45(6):435-41. PMID: 22749725.
73. Kim HB, Park WB, Lee KD, Choi YJ, Park SW, Oh MD, et al. Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea. Journal of clinical microbiology. 2003;41(6):2279-81. doi: 10.1128/jcm.41.6.2279-2281.2003 PMID: 12791836
74. Chung G, Cha J, Han S, Jang H, Lee K, Yoo J, et al. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006. Journal of microbiology and biotechnology. 2010;20(3):637-42. Epub 2010/04/08. PMID: 20372039.
75. Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H, et al. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. Journal of clinical microbiology. 2001;39(12):4445-51. doi: 10.1128/JCM.39.12.4445-4451.2001 PMID: 11724859; PubMed Central PMCID: PMC88563.
76. Hanaki H, Hososaka Y, Yanagisawa C, Otsuka Y, Nagasawa Z, Nakae T, et al. Occurrence of vancomycinintermediate-resistant Staphylococcus aureus in Japan. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy. 2007;13(2):118-21. PMID: 17458681.
77. Sader HS, Jones RN, Rossi KL, Rybak MJ. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. The Journal of antimicrobial chemotherapy. 2009;64(5):1024-8. doi: 10. 1093/jac/dkp319 PMID: 19744978.
78. Parer S, Lotthe A, Chardon P, Poncet R, Jean-Pierre H, Jumas-Bilak E. An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit. Infection control and hospital epidemiology. 2012;33(2):167-74. doi: 10.1086/663703 PMID: 22227986.
79. N A, L NL, K AG, S N. The presence of heterogeneous vancomycin-lntermediate Staphylococcus aureus (heteroVISA) in a major Malaysian hospital. The Medical journal of Malaysia. 2012; (3:).
80. B G, F K, LW, S C, S HG. Presence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Germany. European Journal of Clinical Microbiology and Infectious Diseases. 1999;18(10):691-6. PMID: 10584894
81. Ho CM, Hsueh PR, Liu CY, Lee SY, Chiueh TS, Shyr JM, et al. Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan-SMART program, 2003. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology.. 2010;29(4):383-9. doi: 10.1007/s10096-009-0868-4 PMID: 20155296.
82. Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. Journal of clinical microbiology. 2007;45(5):1511-4. doi: 10.1128/JCM.01262-06 PMID: 17344363; PubMed Central PMCID: PMC1865872.
83. Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrobial agents and chemotherapy. 2009;53(9):3642-9. doi: 10.1128/AAC.00206-09 PMID: 19546358; PubMed Central PMCID: PMC2737858.
84. WY, H YJ, A XM, X HT, S TY. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China. Chin Med J (Engl). 2013;126(3):505-9.
85. Chaudhary M, Payasi A. Prevalence of heterogeneous glycopeptide intermediate resistance in Methicillin-Resistant Staphylococcus aureus. American Journal of Infectious Diseases. 2013;9(3):63-70.
86. Vaudaux P, Ferry T, Uckay I, Francois P, Schrenzel J, Harbarth S, et al. Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology.. 2012;31(12):3367-74. doi: 10.1007/s10096-012-1705-8 PMID: 22833247.
87. Khanal B, Baral R, Acharya A. Prevalence of Vancomycin Intermediate Staphyloccus aureus (VISA) in a tertiary care hospital in Eastern Nepal. International Journal of Infectious Diseases. 2010;14:e342-e3.
88. Bert F, Clarissou J, Durand F, Delefosse D, Chauvet C, Lefebvre P, et al. Prevalence, Molecular Epidemiology, and Clinical Significance of Heterogeneous Glycopeptide-Intermediate Staphylococcus aureus in Liver Transplant Recipients. Journal of clinical microbiology. 2003;41(11):5147-52. doi: 10. 1128/jcm.41.11.5147-5152.2003 PMID: 14605151
89. Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrobial agents and chemotherapy. 2009;53(8):3447-52. doi: 10.1128/AAC.01365-08 PMID: 19506056; PubMed Central PMCID: PMC2715624.
90. Canton R, Mir N, Martinez-Ferrer M, Sanchez Del Saz B, Soler I, Baquero F. [Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides]. Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia. 1999;12(1):48-53. Epub 2000/07/15. PMID: 10896469.
91. K M, T PT, T-K A, L NJ, V AC. Reduced susceptibility to vancomycin of nosocomial isolates of methicillinresistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy. 1999;43(5):729-31. PMID: 10382899
92. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. The Journal of antimicrobial chemotherapy. 2011;66(7):1594-9. doi: 10.1093/jac/dkr169 PMID: 21525024.
93. Bataineh HA. Resistance of Staphylococcus aureus to vancomycin in Zarqa, Jordan. Pakistan Journal of Medical Sciences. 2006;22(2):144-8.
94. Ramli SR, Neoh HM, Aziz MN, Hussin S. Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling. Infectious disease reports. 2012;4(1):e20. PMID: 24470927; PubMed Central PMCID: PMC3892648.
95. Pierard D, Vandenbussche H, Verschraegen I, Lauwers S. [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital]. Pathologie-biologie. 2004;52(8):486-8. doi: 10.1016/j.patbio.2004.07.016 PMID: 15465269.
96. Mlynarczyk A, Mlynarczyk G, Luczak M. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002]. Medycyna doswiadczalna i mikrobiologia. 2003;55(3):209-17. Epub 2004/01/02. PMID: 14702662.
97. F D, C MW, WAH, E MB, WRP. Seeking Vancomycin Resistant Staphylococcus aureus among Patients with Vancomycin-Resistant Enterococci. Clinical Infectious Diseases. 1999;29(6):1566-8. PMID: 10585815
98. Kirby A, Graham R, Williams NJ, Wootton M, Broughton CM, Alanazi M, et al. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. The Journal of antimicrobial chemotherapy. 2010;65(4):721-4. doi: 10.1093/jac/dkq009 PMID: 20124288.
99. Dubey D, Rath S, Sahu MC, Pattnaik L, Debata NK, Padhy RN. Surveillance of infection status of drug resistant Staphylococcus aureus in an Indian teaching hospital. Asian Pacific Journal of Tropical Disease. 2013;3(2):133-42. doi: 10.1016/s2222-1808 (13) 60057-2
100. Guo Y, Wang H, Zhao CJ, Wang ZW, Cao B, Xu YC, et al. A surveillance study of antimicrobial resistance of gram-positive cocci strains isolated from 16 teaching hospitals in China in 2012. Chinese Journal of Microbiology and Immunology (China). 2013;33(6):401-9.
101. Schmitz F-J, Krey A, Geisel R, Verhoef J, Heinz H-P, Fluit AC. Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. European Journal of Clinical Microbiology and Infectious Diseases. 1999;18(7):528-30. PMID: 10482037
102. A HM, WM, G M, J AP, R JF, C BD, et al. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. The Journal of antimicrobial chemotherapy. 2000;46(4):639-40.
103. S B, Y S, G D, G Z, O D, S G, et al. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey. BMC infectious diseases. 2013;13(50):46-54.
104. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J, et al. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. The Lancet. 1999;353(9164):1587-8.
105. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. Journal of clinical microbiology. 2009;47(6):1640-4. doi: 10.1128/JCM.02135-08 PMID: 19369444; PubMed Central PMCID: PMC2691078.
106. Tallent SM, Bischoff T, Climo M, Ostrowsky B, Wenzel RP, Edmond MB. Vancomycin Susceptibility of Oxacillin-Resistant Staphylococcus aureus Isolates Causing Nosocomial Bloodstream Infections. Journal of clinical microbiology. 2002;40(6):2249-50. doi: 10.1128/jcm.40.6.2249-2250.2002 PMID: 12037100
107. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillinresistant S. aureus isolates. Journal of clinical microbiology. 2011;49(1):269-74. doi: 10.1128/JCM. 00914-10 PMID: 20962147; PubMed Central PMCID: PMC3020454.
108. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. Journal of clinical microbiology. 2000;38(10):3879-81. PMID: 11015427
109. Pastagia M, Kleinman LC, Cruz EGLdl, Jenkins SG. Predicting risk for death from MRSA bacteremia. Emerging Infectious Diseases. 2012;18(7):1072-80. doi: 10.3201/eid1807.101371 PMID: 22709685
110. CG G. Glycopeptide resistance in Staphylococcus aureus: is it a real threat? Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy. 2004;10(2):69-75.
111. T Y, N K, T Y, I K, I M, WY, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. Journal of Infection and Chemotherapy. 2011;17(1):52-7. PMID: 20625789
112. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54(1):51-8. Epub 2011/11/24. doi: 10.1093/cid/cir764 PMID: 22109947.
113. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis. 2001;7(2):327-32. Epub 2001/04/11. PMID: 11294734; PubMed Central PMCID: PMCPmc2631729.
114. Saito M, Katayama Y, Hishinuma T, Iwamoto A, Aiba Y, Kuwahara-Arai K, et al. "Slow VISA", a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. Antimicrobial agents and chemotherapy. 2014;58(9):5024-35. Epub 2014/05/21. doi: 10.1128/aac.02470-13 PMID: 24841271; PubMed Central PMCID: PMCPmc4135821.
115. Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. The Journal of infection. 2010;60(2):140-5. Epub 2009/12/08. PMID: 19961873.
116. Chang W, Ma X, Gao P, Lv X, Lu H, Chen F. Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Indian journal of medical microbiology. 2015;33(2):262-6. Epub 2015/04/14. doi: 10.4103/0255-0857.148837 PMID: 25865979.
117. Chen CJ, Huang YC. New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect. 2014;20(7):605-23. Epub 2014/06/04. doi: 10.1111/1469-0691.12705 PMID: 24888414.
118. K Y, I T, H K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2000;44(6):: 1549-55. PMID: 10817707
119. N TS, L KH, C-S K, B SM, B DJ, E J, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290(22):2976-84. PMID: 14665659
120. K SL, M WJ, N GR. In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur? International journal of antimicrobial agents. 2006;27(2):168-70. PMID: 16420976
121. E J, E-G C, S I, L AR, G L. Carriage frequency, diversity and methicillin resistance of Staphylococcus aureus in Danish small ruminants. Veterinary Microbiology. 2013;163:110-5. doi: 10.1016/j.vetmic. 2012.12.006 PMID: 23290574
122. Aires De Sousa M, Conceicao T, Simas C, De Lencastre H. Comparison of genetic backgrounds of methicillin-resistant and -susceptible Staphylococcus aureus isolates from Portuguese hospitals and the community. Journal of clinical microbiology. 2005;43(10):5150-7. Epub 2005/10/07. doi: 10. 1128/jcm.43.10.5150-5157.2005 PMID: 16207977; PubMed Central PMCID: PMCPmc1248511.
123. L M, D X, V AE, D BA, WD, S Y, et al. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nature Medicine. 2012;18(5):816-9. doi: 10.1038/nm.2692 PMID: 22522561
124. JP H. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137-59. PMID: 19381330